Galapagos’ target discovery platform is based on adenoviruses that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins. High-throughput assays that represent a selected human disease state are then used to functionally select for those proteins that have a causative effect in those models of human disease. After rigorous validation of these protein targets, they form the basis for the development of drugs. Galapagos is convinced that the targets identified by its technology are of such high quality that they have an enhanced chance of leading to a successful introduction of a new drug on the market

In addition to forming the basis of Galapagos’ internal target discovery activities, these adenoviral collections and screening technology are also made available to pharmaceutical companies and academic institutes through BioFocus DPI , Galapagos’ services unit. Numerous partners have already applied Galapagos’ technology across a number of disease areas, aiding the pharmaceutical and scientific communities to better understand the cause of disease and further progressing the development of new drugs.

To view the contents of the knock-down collection, go to the SilenceSelect database.

To view the contents of the full-length over-expression collection, go to the FLeXSelect database.

Or e-mail adeno@glpg.com for more information.

 

BioFocus DPI offers a complete range of pre-clinical expertise for discovery biology, medicinal chemistry, ADME and molecular informatics to pharmaceutical and biotechnology companies. BioFocus DPI is a recognized expert in five key areas of drug discovery - assay development and screening, hit finding, hit-to-lead, lead optimization and ADME testing. Its extensive computational design capabilities and automated chemistry facilities are available to clients, and have been used to design and create the world’s leading brand of hit-finding libraries, the SoftFocus® collection. In addition, BioFocus DPI has the largest commercially-available diversity compound collection with over 700,000 characterized synthetic compounds and a unique collection of natural compounds originating from bacteria and fungi. BioFocus DPI both supplies and screens internally these chemical collections as hit-finding solutions. Within the Basel facility, BioFocus DPI has ultra high-throughput screening capabilities to analyze these compound collections against a wide range of protein targets. Together with the Chematica™ and Admensa™ products, which facilitate target and compound selection and prioritization, BioFocus DPI can offer the broadest target-to-drug products and services to its customers.

For more information, visit the BioFocusDPI website.